MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies
Business Wire•14/10/2026•08:01 ET
2
Key Highlights
- ➤MindWalk (HYFT) appoints three senior Boston-based development leaders.
- ➤Pipeline advances toward preclinical efficacy studies.
- ➤Zachary Maben named Director, Antigen Discovery & Protein Engineering.
- ➤Joanne Lim named Director, Preclinical Development.
- ➤Shuji Sato expands VP, Innovative Solutions role to include MindWalk’s pipeline.
Expert Statements
Jennifer Bath, President and Chief Executive Officer, MindWalk Holdings Corp.
“Preclinical efficacy is where a program’s value starts to be defined, and it is the stage our pipeline is now approaching. Joanne has taken programs from concept through candidate nomination and knows what an efficacy package has to show. Zachary gives us internal structural confirmation that a construct presents what we designed before it enters animal studies. Shuji brings twenty years of antibody development and a working knowledge of our platform and partners to the question of which assets deserve continued investment. Where our programs run on ReefIQ™ and LensAI™, what they generate feeds back into the platform our partners use, so the pipeline and the platform strengthen each other.”
MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies
Senior appointments from Pfizer, Novartis, Arbor Biotechnologies, and Orum Therapeutics bring preclinical development, structural biology, and portfolio strategy depth as MindWalk prepares its programs for preclinical efficacy studies
Get started
Create a free account to read the full story.